罗格列酮对2型糖尿病患者血脂及内脂素的影响

目的：观察罗格列酮对2型糖尿病（T2DM）患者血脂及内脂素（Visfatin）的影响，分析临床治疗效果。方法：收集本院内分泌科2010年1月-2012年1月收治的T2DM患者84例，随机均分为对照组和罗格列酮治疗组。比较治疗前后空腹血糖（Fastingplasmaglucose，FPG）、Hbalc、TC、TG、低密度脂蛋白（Lowdensitylip—oprotein，LDL）、高密度脂蛋白（Highdensitylipoprotein，HDL）、内脂素等生化指标变化情况。结果：治疗前两组FPG、Hbalc、TC、TG、LDL、HDL和内脂素的表达无统计学差异（P〉0．05）。治疗后两组FPG和Hbalc的表达水平均显著减低（P〈0．05，P〈0．01），罗格列酮组FPG和Hbalc减低幅度显著高于对照组（P〈0．05）。对照组治疗前后TC、TG、LDL、HDL和内脂素的表达差异无统计学意义（P〉0．05），罗格列酮组治疗后TC、TG、LDL和内脂素表达明显低于治疗前（P〈0．05，P〈0．01），HDL明显高于治疗前（P〈0．05）。罗格列酮组临床治疗有效率（95．2％）明显高于对照组（P〈0．05）。罗格列酮组不良反应发生率（23．8％）与对照组（21．4％）比较无统计学差异（P〉0．05）。结论：罗格列酮具有高效的降血糖作用，可以显著降低T2DM患者的血脂和内脂素水平，临床疗效显著，不良反应率低，建议在临床推广应用。

Effects of rosiglitazone on lipid and visfatin in patients with type 2 di- abetes mellitus

AIM： To investigate the effects of rosiglitazone on lipid and visfatin in patients with type 2 diabetes mellitus （T2DM） and anal ysis its clinical efficacy. METHODS： A total of 84 patients with T2DM were enrolled in this study. All cases were divided into control group （n=42） and rosiglitazone treatment group （n= 42）. Before and after the treatment, FPG, Hhalc, TC, TG, LDL, HDL, visfatin and other biochemical indicators were compared. RE SULTS： Before treatment, FPG, Hbalc, TC, TG, LDL , HDL and visfatin had no significant difference between the two groups （P〉0.05）. After treatment, FPG el were significantly and Hbalc expression lev reduce （P〈0.05, P 0.01）, the rosiglitazone group FPG and Hbalc reduce amplitude were significantly higher than that control group （P〈0.05）. Before and after treatment, treatment group TC, TG, LDL,HDL and visfatin expression difference was not statistically significant （P 〈0.05）, the treat ment group TC, TG, LDL and visfatin express were significantly lower than before treatment （P〉0.05, P〉0.01）, HDL were significantly higher than before treatment （P 〈 0.05）. Ros iglitazone group clinical efficient （95.2%） were higher than that control group （P〈0.05）. The adverse reaction rates of rosiglitazone group （23.8%） and control group （21.4%） showed no significant difference （P 〈 0.05 ）. CONCLU SION： Rosiglitazone treatment showed more ef fective to reduce the serum level of glucose, lipid and visfatin, with the low rate of adverse reac tions.